SCHEMBL21144233

SCHEMBL21144233

CCOC(=O)c1ccn(-c2cc(NC3CCC(F)(F)CC3)cc(Cl)n2)n1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.37
ALDH1A1 P00352 1/20 0.37
TP53 P04637 1/20 0.37
HPGD P15428 1/20 0.37
HSD17B10 Q99714 1/20 0.37
FAAH O00519 5/20 0.36
CNR1 P21554 2/20 0.36
MAPT P10636 1/20 0.35
THRB P10828 1/20 0.35
JAK2 O60674 1/20 0.35
JAK1 P23458 1/20 0.35
TYK2 P29597 1/20 0.35
JAK3 P52333 1/20 0.35
S1PR2 O95136 1/20 0.35
IDH1 O75874 2/20 0.35
IDH2 P48735 1/20 0.34
NOS1 P29475 1/20 0.34
NOS2 P35228 1/20 0.34
P2RX3 P56373 1/20 0.33
KDM1A O60341 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21143739 0.89 IDH1 (0.41) KDM4EALDH1A1TP53HPGDHSD17B10
SCHEMBL31127054 0.89 IDH1 (0.41) KDM4EALDH1A1TP53HPGDHSD17B10
SCHEMBL21143686 0.86 NOS2 (0.41) KDM4EALDH1A1TP53HPGDHSD17B10
SCHEMBL19687210 0.84 KDM4E (0.42) KDM4EALDH1A1TP53HPGDHSD17B10
SCHEMBL31127166 0.82 IDH1 (0.41) MAPTIDH1IDH2
SCHEMBL21143856 0.82 IDH1 (0.41) MAPTIDH1IDH2
SCHEMBL19686761 0.81 KDM4E (0.36) KDM4EALDH1A1TP53HPGDHSD17B10
SCHEMBL21144060 0.81 IDH1 (0.36) KDM4EALDH1A1TP53HPGDHSD17B10
SCHEMBL21143756 0.80 KDM4E (0.36) KDM4EALDH1A1TP53HPGDHSD17B10
SCHEMBL31127142 0.80 KDM4E (0.36) KDM4EALDH1A1TP53HPGDHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240317705-A1 POTASSIUM CHANNEL MODULATORS NOVARTIS AG (CH) 2024-09-26 US disclosed
US-10774064-B2 Potassium channel modulators CADENT THERAPEUTICS, INC. (US) 2020-09-15 US disclosed
US-10774064-B2 Potassium channel modulators CADENT THERAPEUTICS, INC. (US) 2020-09-15 US disclosed
US-20190218200-A1 POTASSIUM CHANNEL MODULATORS NOVARTIS AG (CH) 2019-07-18 US disclosed
US-20190218200-A1 POTASSIUM CHANNEL MODULATORS NOVARTIS AG (CH) 2019-07-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240317705-A1 POTASSIUM CHANNEL MODULATORS KCNJ11, KCNJ2, KCNJ1 KDM4E 1648/4885ALDH1A1 1320/4885TP53 4644/4885
US-10774064-B2 Potassium channel modulators KCNJ11, KCNJ2, KCNJ1 KDM4E 1648/4885ALDH1A1 1320/4885TP53 4644/4885
US-20190218200-A1 POTASSIUM CHANNEL MODULATORS KCNJ11, KCNJ2, KCNJ1 KDM4E 1648/4885ALDH1A1 1320/4885TP53 4644/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.